Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Bayer outsources chemistry R&D to Nuvisan
by Rick Mullin
February 15, 2020
| A version of this story appeared in
Volume 98, Issue 7
Bayer will transfer most of its Berlin-based small-molecule drug research to Nuvisan, a German research services firm with expertise in clinical studies, lab services, and contract manufacturing. Nuvisan will take over a center on Bayer’s Berlin campus that employs about 400 researchers focused on activities including lead discovery, medicinal chemistry, and drug metabolism studies. Sanofi entered a similar partnership in 2015 when it transferred its small-molecule site in Toulouse, France, to the services firm Evotec.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter